Medical Proteogenomics News
-
BOC Sciences to Present Its Novel Solutions at the 2024 TIDES USA Conference
BOC Sciences, a globally renowned supplier with over a decade of experience in the biochemical supply chain, is thrilled to announce its participation in this year's TIDES USA or the Oligonucleotide and Peptide Therapeutics conference. The BOC Sciences team will showcase its cutting-edge products and services at booth #937. TIDES USA 2024 is to be held in Boston from May 14 to 17, 2024, ...
By BOC Sciences
-
Almirall and etherna enter into a multi-target alliance to develop mRNA-based therapies in medical dermatology
The multi-target research and development partnership will focus on severe skin diseases The collaboration leverages etherna’s proprietary mRNA and lipid nanoparticle (LNP) technology with Almirall’s expertise in the dermatology space In addition to upfront and technology access payments, etherna is eligible to receive €300 million in development and commercial ...
By eTheRNA
-
BOC Sciences Celebrates Nobel Prize Awarded to Scientists Behind COVID-19 Vaccines
BOC Sciences expressed its congratulations to Katalin Karikó and Drew Weissman for being recipients of the 2023 Nobel Prize in Physiology or Medicine. The Royal Swedish Academy of Sciences recognized Dr. Karikó and Dr. Weissman's remarkable contributions to science, specifically acknowledging their game-changing discoveries in nucleoside base modifications. BOC Sciences, which ...
By BOC Sciences
-
Alfa Chemistry Excels in mRNA Vaccine Development, Production, Optimization, and Quality Control
In the face of global health crises such as the COVID-19 pandemic, the development and production of vaccines have become paramount to safeguarding public health and restoring normalcy. Among the various vaccine technologies, mRNA vaccines have emerged as a groundbreaking solution, offering promising results in the fight against infectious diseases. Alfa Chemistry, a renowned scientific research ...
-
Creative Enzymes Unveils Advanced Substrate, Inhibitor, and Ligand Screening Services
Creative Enzymes, an esteemed frontrunner in the field of enzyme-related solutions, is excited to introduce an innovative suite of screening services designed to cater to the evolving needs of today's scientific community. In the ever-changing realm of scientific research, the importance of comprehensive and dependable screening for substrates, inhibitors, and ligands has become increasingly ...
-
Alfa Chemistry Announces the Launch of Innovative IVD Products for Laboratory Use
In vitro diagnostics (IVD) are tests done on samples such as blood or tissue for the purpose of detecting diseases or other conditions. To facilitate efforts on IVD research, the US-based chemical supplier Alfa Chemistry has recently introduced three IVD products for laboratory use, adding to its already diverse range of biological reagents. The biological reagents previously launched by Alfa ...
-
mRNA/LNP technology platform company etherna names Bernard Sagaert as Chief Executive Officer and Marijn Dekkers as Chairman of the Board
Sagaert’s CEO appointment follows his successful interim period implementing etherna’s new partnership-driven business strategy. Sagaert joined etherna in 2017 and brings extensive operational and strategic experience in the life sciences industry. Dekkers, who is the founder of investment and advisory firm Novalis Capital Partners LLC and former CEO of Bayer AG and Thermo ...
By eTheRNA
-
Dyadic and bYoRNA Announce a Collaboration Targeting the Production of Abundant, Low-Cost mRNA From C1-Cells
Dyadic International, Inc. (“Dyadic”) (NASDAQ: DYAI) and bYoRNA SAS (“bYoRNA”) today announced that they entered into a development and commercialization agreement to work on disruptive bioproduction technologies that will help exploit the therapeutic potential of messenger RNA (“mRNA”). Dyadic is a global biotechnology company focused on building innovative ...
-
Creative Proteomics Leads the Way with Cutting-Edge RNA Pull Down Service
Creative Proteomics, a trailblazer in the realm of proteomics and genomics services, is proud to introduce its groundbreaking RNA Pull Down Service, poised to revolutionize the study of RNA-protein interactions. This transformative service transcends the boundaries of traditional methodologies, empowering researchers to unlock the enigma of cellular mechanisms and disease pathways. RNA-protein ...
-
BOC Sciences Adds World Vaccine Congress Europe to Its 2023 Event Calendar
"End-to-End Support for Your Pharmaceutical Journey", with the commitment to researchers, BOC Sciences will attend the renowned World Vaccine Congress Europe in Barcelona, Spain, from 16 to 19 Octobe World Vaccine Congress Europe has become the world's largest and most established meeting dedicated to vaccines. It brings together the professionals and companies that are shaping the future of ...
By BOC Sciences
-
Creative Proteomics Debuts Far-Western Blot Analysis Service to Advance Proteomics Research
Creative Proteomics, a prominent provider of proteomics services, has recently unveiled its highly anticipated Far-Western Blot Analysis service. This service has the potential to transform our understanding of complex protein-protein interactions, opening new avenues for advancements in drug discovery and therapeutic development. Protein-protein interactions serve as the building blocks of ...
-
CD Computabio Unleashes the Power of Computational Biology with Innovative Virtual Screening Service
CD Computabio, a prominent provider of computational biology solutions, is excited to introduce its virtual screening service based on pharmacophore fragments. This approach is poised to revolutionize the field of drug discovery by offering researchers an efficient and cost-effective solution for identifying promising drug candidates. In the early stages of drug development, virtual screening ...
-
Creative Proteomics Unveils Revolutionary Co-IP Service Empowering Breakthroughs in Protein-Protein Interaction Research
Creative Proteomics, a global leader in proteomics services, proudly announces the launch of its cutting-edge Co-immunoprecipitation (Co-IP) service. This advanced offering enables researchers to explore protein-protein interactions and gain valuable insights into complex cellular processes. Protein-protein interactions are the cornerstone of numerous biological processes, playing a pivotal ...
-
Creative Proteomics Launches Crotonylation Proteomics Analysis Service to Enhance Your Epigenetic Research
Creative Proteomics, a leading provider of proteomics, metabolomics, and bioinformatics services, is pleased to announce the launch of its new Crotonylation Proteomics Analysis Service. This service is designed to provide researchers with a comprehensive and in-depth analysis of crotonylation, a newly discovered post-translational modification (PTM) of lysine residues. Crotonylation, a recently ...
-
Bayer strengthens gene therapy portfolio with lipid nanoparticle technology from Acuitas Therapeutics
Clinically validated lipid nanoparticle (LNP) delivery technology will further strengthen Bayer’s gene therapy portfolio High potency ionizable lipid technology and LNP carriers allow for efficient, targeted, and transient delivery of gene editing RNA components to the liver Bayer AG is joining forces with Acuitas Therapeutics, Inc., a biotechnology company specializing in the ...
By Bayer AG
-
Bayer receives U.S. FDA Fast Track Designation for asundexian atrial fibrillation program
The OCEANIC-AF (atrial fibrillation) study with asundexian is part of the Phase III OCEANIC clinical trial program enrolling more than 27,000 patients in over 40 countries Asundexian is being evaluated as a potential improved treatment option in stroke prevention and could be part of an entirely new class of treatment options in thrombosis management that aims to uncouple efficacy from ...
By Bayer AG
-
BOC Sciences Unveils Comprehensive Capabilities of Custom Peptide Drug Conjugate
BOC Sciences, a leading CRO in the USA, unveils its comprehensive capabilities for custom peptide drug conjugate from project design to commercial production. With its well-established conjugation platform, BOC Sciences supports pharmaceutical and biotechnology clients at the forefront of drug conjugation. Peptide-drug conjugates (PDCs) are mainly used in anti-cancer therapy, which integrates the ...
By BOC Sciences
-
CD Bioparticles Launches mRNA Transfection Reagents for Research Applications
CD Bioparticles, a leading manufacturer and supplier of numerous drug delivery products and services, recently introduced a line of highly efficient mRNA Transfection Reagents with low toxicity for research applications, including the mRNA Transfection Reagent, Stem mRNA Transfection Reagent, and mRNA/gRNA Transfection Reagent. mRNA transfection is the process of introducing and expressing mRNA ...
-
Alfa Chemistry-A New Supplier of Vaccine Excipients, Nucleic Acid Delivery Excipients and SARS-CoV-2 Detection Raw Materials
Alfa Chemistry, known as a chemical supplier for various high-quality chemicals and materials for both academia and the industry, has recently extended its offering scope to vaccine related products, including but not limited to: vaccine excipients, nucleic acid delivery excipients, cell culture media and pharmaceutical packaging. “Always bearing in mind that what customers truly need is the top ...
-
Visit of His Majesty the King of the Belgians Philippe and Her Majesty the Queen of the Belgians Mathilde to Afrigen Biologics
HM King Philippe and HM Queen Mathilde, currently on a state visit to South Africa until March 27, visited the Afrigen Biologics facility in Cape Town to learn more about how two Belgian companies, Univercells and etherna, are supporting the development of the first African- developed mRNA COVID-19 vaccine. The King and The Queen are accompanied by five ministers of federal and regional ...
By eTheRNA
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you